Brief: Atea Pharmaceuticals Highlights Strategic Priorities For 2022
07/01/2022 12:16
Jan 7 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS HIGHLIGHTS STRATEGIC PRIORITIES FOR
2022
* ATEA PHARMACEUTICALS INC - PLANNING GLOBAL PHASE 2
OUTPATIENT
TRIAL FOR BEMNIFOSBUVIR (AT-527) DESIGNED TO SUPPORT ANTICIPATED
COMBINATION TRIALS
* ATEA PHARMACEUTICALS INC - ATEA IS ADVANCING AT-752 TO A
PHASE 2
PROOF-OF-CONCEPT PROGRAM FOR TREATMENT OF DENGUE FEVER.
Source text for Eikon: ID:nGNX4N6vRw
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM